Medicenna Therapeutics Corp saw a notable gain in its stock price during yesterday's trading session, reflecting positive investor sentiment.
Shares of Medicenna Therapeutics Corp (MDNA.TO) went up by 3.26%, closing at CA$0.47. This increase comes amid ongoing developments in the biotech sector, where investor interest remains high.
Investor takeaway: The recent rise in Medicenna's stock price suggests growing confidence in its pipeline and overall market positioning, making it a stock to watch for those interested in biotech.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$43.84M
52W high
$1.97
52W low
$0.34
1W change
+15.85%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 573.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+573.7% Upside
Current Price
C$0.47
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
60.9%
Annualized
90-Day Vol
71.2%
Annualized
Trend (90d)
+18.1%
Annualized drift
90d Mean
C$0.51
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.49 | C$0.39 – C$0.60 |
| 60 trading days | C$0.50 | C$0.37 – C$0.67 |
| 90 trading days | C$0.51 | C$0.35 – C$0.73 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medicenna's stock surged by 3.26% yesterday.
The market cap of Medicenna Therapeutics Corp is approximately CA$43.84 million, indicating it is a relatively small player in the biotech space, which can lead to higher volatility.
Bull case
Medicenna's recent advancements in its clinical programs and strong patent estate could attract more investment, potentially driving further appreciation in its stock price.
Bear case
Despite the recent gains, the company still faces challenges, including a lack of immediate revenue generation and the inherent risks that come with biotech investments.
Market Performance Overview
Advertisement
Medicenna's stock performance yesterday marked a significant uptick, closing at CA$0.47. This increase reflects a broader trend in the biotech sector, where companies are gaining traction as investors seek opportunities in innovative therapies.
Factors Behind the Gain
While there were no specific announcements from Medicenna that directly influenced the stock price, the overall market sentiment towards biotech firms remains positive. The company's ongoing development of its lead programs and recent patent approvals may have contributed to investor optimism.
Looking Ahead
Investors should keep an eye on Medicenna's upcoming announcements, especially regarding clinical trial results and any new partnerships. These factors could significantly impact the stock's performance in the near future. For more insights, check out our detailed analysis on Medicenna's stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
